Answers are grounded in this paper and cite their sources.
Background Imipenem resistance in Escherichia coli within intensive-care settings (ICU) compromises effective empiric and targeted therapy and is associated with worse outcomes. Objectives To quantify the global prevalence of imipenem-resistant E. coli (IR-EC) in ICU/NICU isolates, characterize between-study heterogeneity and temporal trends, and summarize distribution patterns by geography, health-system context, and laboratory methods. Methods We searched PubMed/MEDLINE, EMBASE, Scopus, and Web of Science from inception to 1 June 2025. Observational studies reporting IR-EC proportions (R/N) in ICU/NICU were included. Random-effects meta-analysis of proportions (variance-stabilized; back-transformed) was conducted. Heterogeneity (Q, τ 2 , I 2 ), subgroup analyses (country/WHO region, income level, AST method/guideline, period), and year-wise meta-regression were prespecified. Small-study effects were examined with Begg/Egger tests and Doi plot with LFK index; trim-and-fill assessed robustness. Risk of bias used the JBI prevalence checklist. Results Forty-two studies comprising 15,227 isolates (752 resistant) were included from multiple countries and WHO regions. The pooled IR-EC prevalence was 9.5% (95% CI 5.6–15.7%; Q(41)=1462.276, I 2 =97.2%, p<0.001). Trim-and-fill yielded 10.3% (95% CI 6.0–17.0%). Prevalence varied markedly: lowest in the United States (0.5%) and highest in Peru (85.7%). By WHO region, the Western Pacific pooled at 4.6% versus 38.4% in South-East Asia. By income level, lower-middle-income settings pooled at 32.5% versus 8.4% in upper-middle-income and 9.1% in high-income settings. Methodologically, broth microdilution studies pooled at 4.6% compared with disc diffusion 19.7% and automated systems 19.3%. Year-wise meta-regression indicated a significant upward trend (r=0.113, p=0.005, 95% CI 0.034–0.192). The Doi plot suggested major asymmetry (LFK=4.84), while Begg (p=0.651) and Egger (p=0.867) were non-significant. Conclusions Imipenem-resistant E. coli affects about 10% of ICU/NICU isolates globally, with wide geographic and methodological variation and a significant rising trend over time. These results highlight the need for improved antimicrobial stewardship, standardized susceptibility testing, and enhanced molecular surveillance to guide empiric therapy in critical care settings.
No takes yet. Share an insight, caveat, or question.
Farhan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: